Hims & Hers Health (NYSE:HIMS) Rating Lowered to Neutral at Citigroup

Hims & Hers Health (NYSE:HIMSGet Free Report) was downgraded by analysts at Citigroup from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. They currently have a $20.00 target price on the stock, up from their previous target price of $16.00. Citigroup’s target price points to a potential upside of 26.38% from the company’s current price.

A number of other research firms also recently weighed in on HIMS. Canaccord Genuity Group began coverage on shares of Hims & Hers Health in a research note on Wednesday, April 10th. They set a “buy” rating and a $20.00 price target on the stock. Guggenheim raised their price target on shares of Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Tuesday, February 27th. Jefferies Financial Group reiterated a “hold” rating and issued a $15.00 price objective (down from $17.00) on shares of Hims & Hers Health in a research note on Tuesday, April 16th. Seaport Res Ptn restated a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Finally, Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a research report on Tuesday, May 7th. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $15.69.

Get Our Latest Report on Hims & Hers Health

Hims & Hers Health Trading Down 2.1 %

NYSE HIMS opened at $15.83 on Wednesday. The company has a market cap of $3.40 billion, a P/E ratio of -1,582.50 and a beta of 0.97. Hims & Hers Health has a 1 year low of $5.65 and a 1 year high of $20.11. The company has a fifty day simple moving average of $14.11 and a 200 day simple moving average of $11.04.

Hims & Hers Health (NYSE:HIMSGet Free Report) last issued its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. During the same period in the previous year, the company earned ($0.05) earnings per share. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. Equities research analysts forecast that Hims & Hers Health will post 0.18 EPS for the current fiscal year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Soleil Boughton sold 63,621 shares of Hims & Hers Health stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $15.17, for a total value of $965,130.57. Following the completion of the sale, the insider now owns 154,345 shares in the company, valued at approximately $2,341,413.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Andrew Dudum sold 50,361 shares of the company’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $16.34, for a total transaction of $822,898.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 63,621 shares of the stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $15.17, for a total transaction of $965,130.57. Following the sale, the insider now owns 154,345 shares in the company, valued at $2,341,413.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 594,553 shares of company stock valued at $8,454,738. Insiders own 17.71% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several institutional investors and hedge funds have recently modified their holdings of the business. Graham Capital Management L.P. increased its holdings in shares of Hims & Hers Health by 39.4% during the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock worth $2,141,000 after buying an additional 96,277 shares in the last quarter. Forerunner Ventures Management LLC acquired a new position in Hims & Hers Health in the 4th quarter worth about $86,836,000. Swiss National Bank boosted its stake in shares of Hims & Hers Health by 9.2% during the third quarter. Swiss National Bank now owns 309,200 shares of the company’s stock valued at $1,945,000 after purchasing an additional 26,100 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Hims & Hers Health by 3.1% during the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after purchasing an additional 428,671 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of Hims & Hers Health by 11.5% in the third quarter. Bank of New York Mellon Corp now owns 564,501 shares of the company’s stock valued at $3,551,000 after buying an additional 58,288 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.

Read More

Analyst Recommendations for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.